Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atherosclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    194 result(s) found for: Atherosclerosis. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-004950-27 Sponsor Protocol Number: VAL-02 Start Date*: 2014-02-06
    Sponsor Name:Sahlgrenska universitetssjukhuset
    Full Title: Effect of valproic acid on fibrinolysis in humans with atherosclerosis
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014618-80 Sponsor Protocol Number: CACZ885I2206 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident ath...
    Medical condition: atherosclerosis type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    14.1 10047065 - Vascular disorders 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005924-97 Sponsor Protocol Number: cro1120 Start Date*: 2008-10-23
    Sponsor Name:Imperial College
    Full Title: A 12 week observational study to evaluate the effects of the initiation of chemotherapy with anti-angiogenic activity on neovascularisation (as determined by contrast enhanced ultrasound, (CEUS)) w...
    Medical condition: Carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002677-53 Sponsor Protocol Number: CL2-78989-009 Start Date*: 2012-12-19
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wa...
    Medical condition: Arterial wall inflammation in patients with marked atherosclerotic plaque inflammation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10057703 Coronary atherosclerosis of non-autologous biological bypass graft LLT
    16.0 100000004849 10058152 Coronary atherosclerosis of bypass graft LLT
    16.0 100000004866 10018104 Generalized and unspecified atherosclerosis LLT
    16.0 100000004866 10002892 Aortic atherosclerosis LLT
    16.0 100000004849 10011093 Coronary atherosclerosis LLT
    16.0 100000004866 10003603 Atherosclerosis generalized LLT
    16.0 100000004849 10011095 Coronary atherosclerosis of native coronary artery LLT
    16.0 100000004866 10003605 Atherosclerosis of aorta LLT
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    16.0 100000004849 10011094 Coronary atherosclerosis of autologous biological bypass graft LLT
    16.0 100000004849 10011076 Coronary artery atherosclerosis LLT
    16.0 100000004849 10011097 Coronary atherosclerosis of unspecified vessel LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005650-35 Sponsor Protocol Number: CHDR1503 Start Date*: 2016-04-04
    Sponsor Name:Centre for Human Drug Research
    Full Title: Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein
    Medical condition: Healthy male volunteers
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005893-29 Sponsor Protocol Number: atp01 Start Date*: 2008-08-14
    Sponsor Name:RUNMC
    Full Title: Does ATP cause Annexin A5 targeting in the human forearm?
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-003929-27 Sponsor Protocol Number: STRADIVARIUS Start Date*: 2005-04-14
    Sponsor Name:SANOFI-SYNTHELABO
    Full Title: Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (IntraVascular UltraSo...
    Medical condition: Inhibition of coronary atherosclerosis progression in overweight patients with a cluster of risk factors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002269-14 Sponsor Protocol Number: NL80263.018.21 Start Date*: 2022-08-11
    Sponsor Name:AMC, Cardiovascular Sciences
    Full Title: Dotatate to locate coronary plaques at high-risk of myocardial infarction
    Medical condition: Inflammatory atherosclerosis of the coronary arteries.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005338-35 Sponsor Protocol Number: PM1111138 Start Date*: 2009-04-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT im...
    Medical condition: GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022970-14 Sponsor Protocol Number: CACZ885M2301 Start Date*: 2011-05-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SE (Prematurely Ended) PL (Completed) LV (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) EE (Completed) GR (Completed) IS (Prematurely Ended) BE (Completed) NO (Completed) CZ (Completed) IT (Completed) BG (Prematurely Ended) SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001612-49 Sponsor Protocol Number: EFC5828 Start Date*: 2005-09-05
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by carotid artery intima-media...
    Medical condition: Overweight patients with additional risk factors. Atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004090-29 Sponsor Protocol Number: AVD100521 Start Date*: 2005-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd [...]
    1. GlaxoSmithKline Research & Development Ltd
    2. GlaxoSmithKline R&D
    Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ...
    Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003630-16 Sponsor Protocol Number: GEIDENo.D00112 Start Date*: 2013-04-10
    Sponsor Name:German Heart Centre Munich, Department of
    Full Title: A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB– Ticagrelo...
    Medical condition: Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005839-28 Sponsor Protocol Number: 0859-019 Start Date*: 2008-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients ...
    Medical condition: Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) HU (Completed) FR (Completed) AT (Completed) FI (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005447-25 Sponsor Protocol Number: INTIMA Start Date*: 2013-02-22
    Sponsor Name:Academic Medical Center Amsterdam, department of Internal Medicine
    Full Title: The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000192-14 Sponsor Protocol Number: TMC-CAN-05-02 Start Date*: 2006-12-21
    Sponsor Name:The Medicines Company
    Full Title: A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention
    Medical condition: Subjects with coronary atherosclerosis who require PCI (with or without stent).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003011-58 Sponsor Protocol Number: CACZ885M2301S2 Start Date*: 2012-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001983-31 Sponsor Protocol Number: 1842012 Start Date*: 2012-05-25
    Sponsor Name:Juha Hartikainen
    Full Title:
    Medical condition: Coronary artery by-pass surgery patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002911-16 Sponsor Protocol Number: na Start Date*: 2016-12-28
    Sponsor Name:Maastricht University Medical Center
    Full Title: PET/MRI and plaque vulnerability A feasibility study of 18F-Flutemetamol in atherosclerosis
    Medical condition: Atherosclerosis in the carotids and coronary arteries.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024182-44 Sponsor Protocol Number: NL3372110110 Start Date*: 2011-01-12
    Sponsor Name:
    Full Title: Pilot study: Leucocyte actIvation and endothelial function after oral fat loading combined with VITamin D
    Medical condition: Endothelial function Leukocyte activation Triglyceride metabolism Skin autofluorescence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003601 Atherosclerosis LLT
    12.1 10020870 Hypertriglyceridemia LLT
    12.1 10050713 Vitamin D LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:41:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA